Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Trinh Phan-Canh has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathogenicity and virulence of Candida auris

    by Trinh Phan-Canh, Saskia Seiser, Manju Chauhan, Karl Kuchler, Neeraj Chauhan, Adelheid Elbe-Bürger


  • Open Access

    Cytochrome bc1 Catalytic Subunit Rip1 Modulates Antifungal Tolerance in Candida auris

    by Trinh Phan-Canh, Michaela Lackner, Manju Chauhan, Lisa-Maria Zenz, Neeraj Chauhan, Karl Kuchler

    Candida auris is an emerging fungal pathogen causing invasive infections in immunocompromised patients, with mortality rates reaching up to 60%. Pronounced drug resistance makes treatment failure common, and so does antifungal tolerance, a phenomenon enabling pathogen survival at supra-MIC concentrations without resistance mutations. Here, we uncover a mechanism of antifungal tolerance in C. auris engaging the mitochondrial cytochrome bc1 complex. Deletion of RIP1, a conserved catalytic complex subunit, does not significantly alter the susceptibility to caspofungin or voriconazole. However, rip1Δ mutants exhibit a marked reduction in antifungal tolerance across a wide range of supra-MIC concentrations. Transcriptomics reveals the dysregulation of multiple drug resistance and tolerance-related genes in the rip1Δ mutant, demonstrating a role for Rip1 in controlling antifungal susceptibility. Targeting cytochrome bc1 function with the fungal-specific inhibitor Inz-5 enhances antifungal action of both voriconazole and caspofungin. Additionally, ablation of RIP1 causes fitness defects, suggesting that cytochrome bc1 is a potential antifungal target against C. auris infections.


  • Open Access

    Human keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris

    by Saskia Seiser, Helena Brezovec, Philipp Penninger, Trinh Phan-Canh, Doris Moser, Frank P. Assen, Tanya Ayub, Franziska Rademacher, Regine Gläser, Diana Cerbu, et al.


  • Open Access

    Candida auris can acquire antifungal resistance without selection pressure

    by Trinh Phan-Canh, Duc-Minh Nguyen-Le, Manju Chauhan, Phuc-Loi Luu, Anuradha Chowdhary, Neeraj Chauhan, Karl Kuchler

    The human fungal pathogen Candidozyma auris (formerly Candida auris) can cause prolonged infection outbreaks with high mortality rates in healthcare settings. Treatment failures of patients arise not only from antifungal drug resistance, but also from intra-species variability in pathogenicity as well as induced hypermutation events in response to clinical therapy. Whole genome sequencing was used to identify genetic mutations using the CDC mycoSNPs pipeline. Antifungal susceptibility testing was performed based on Clinical and Laboratory Standards Institute (CLSI) methods. We report here that the interlaboratory exchange of C. auris clinical isolates dried on sterile filter paper, resulted in the emergence of at least three distinct morphotypes following reconstitution. These distinct morphotypes exhibited differences in drug resistance and morphogenesis, linked to the accumulation of mutations in genes associated with azole and echinocandin resistance. Using whole genome sequencing, we identified several variants in TAC1B, MRR1 and FKS2 that correlate with altered drug susceptibilities. Experiments recapitulating filter paper shipment conditions revealed genetic and epigenetic changes, explaining the morphogenetic switching and altered azole resistance. Our findings demonstrate that C. auris can acquire mutations affecting drug resistance traits even in the absence of antifungal exposure, raising concerns about shipment preparation procedures across mycology laboratories. The results are of broad relevance for the medical mycology community, as they call for standardized protocols for exchanging clinical strains, but also experiments to verify phenotypic traits between laboratories.


  • Open Access

    Candida auris skin tropism and antifungal resistance are mediated by carbonic anhydrase Nce103

    by Trinh Phan-Canh, Cristina Coman, Michaela Lackner, Nina Troppmair, Christoph Müller, Diana Cerbu, Saskia Seiser, Philipp Penninger, Irina Tsymala, Narakorn Khunweeraphong, et al.

    The pronounced skin tropism and pan-antifungal resistance of Candida auris pose a serious global health threat. A key question in C. auris biology is how clinical isolates acquire amphotericin B resistance. Here we demonstrate that a carbonic sensing pathway (CSP) contributes to amphotericin B resistance by modulating mitochondrial energy functions in clinical C. auris isolates. Integrated transcriptomics and proteomics identify the carbonic anhydrase Nce103 and its transcription factors Rca1 and Efg1 as important regulatory components of the CSP. The conversion of CO 2 into bicarbonate sustains energy metabolism required for colonization and fitness on human skin and in nutrient-limited microenvironments. We also show that bacterial skin colonizers engage urease to release CO 2 that sustains C. auris fitness and skin colonization. These findings highlight therapeutic options to re-sensitize C. auris to antifungal treatments, as well as to prevent skin colonization by blocking the CSP.


  • Open Access

    Octenidine effectively reduces Candida auris colonisation on human skin

    by Diana Cerbu, Saskia Seiser, Trinh Phan-Canh, Doris Moser, Christian Freystätter, Johannes Matiasek, Karl Kuchler, Adelheid Elbe-Bürger

    Candidozyma (formerly Candida) auris (C. auris), a WHO critical priority pathogen known for its multi-drug resistance and strong skin tropism, is posing a significant health threat. This study evaluates the efficacy of commercial octenidine-based antiseptics in reducing C. auris colonisation on intact and wounded human skin. Using an established ex vivo human skin model to simulate clinical settings, skin samples from healthy donors were exposed to planktonic C. auris cells. Six hours post-contamination, two ready-to-use octenidine-based antiseptics were applied, and fungal colonisation was assessed after 18 h via periodic acid-Schiff staining, bright field and scanning electron microscopy and colony forming unit quantification. In vitro biofilm assays with various C. auris strains, including drug resistant ones, were performed to determine the antifungal effects of octenidine formulations. Results showed that octenidine-based antiseptics significantly reduced C. auris viability on intact and wounded human skin, and also demonstrated a nearly complete eradication across tested strains in vitro. These findings highlight the potential of octenidine-based products in reducing C. auris colonisation, supporting infection prevention and control strategies in healthcare settings and enhancing patient safety.


  • Open Access

    White-Brown switching controls phenotypic plasticity and virulence of Candida auris

    by Trinh Phan-Canh, Sabrina Jenull, Tamires Bitencourt, Saskia Seiser, Doris Moser, Marjan Motamedi, Anuradha Chowdhary, Adelheid Elbe-Bürger, Karl Kuchler


  • Open Access

    Gene dosage of PDR16 modulates azole susceptibility in Candida auris

    by Trinh Phan-Canh, Tamires Bitencourt, Karl Kuchler


  • Open Access

    Rapid in vitro evolution of flucytosine resistance in Candida auris

    by Trinh Phan-Canh, Duc-Minh Nguyen-Le, Phuc-Loi Luu, Narakorn Khunweeraphong, Karl Kuchler

    The pan-antifungal-resistant pathogen Candida auris has been causing high-mortality infection outbreaks in hospitals and healthcare settings. The prodrug 5-fluorocytosine (5FC) is one of four chemical entities, but its clinical use as an antifungal drug has been limited owing to pronounced resistance. However, antifungal combination therapy with 5FC appears as a promising strategy for treating C. auris infections. Here, we show that a C. auris clinical isolate can rapidly acquire genetic mutations to mount 5FC resistance after only one to two passages under drug selection. We exploit a new bioinformatics workflow to identify genetic polymorphisms from RNA-seq data. Strikingly, we identify several mutations in the FUR1 gene encoding the 5-fluorouracil convertase that normally generates the active drug. A single nonsense mutation truncates the enzyme at residue Q30*, leading to 5FC resistance due to inactive Fur1. Whole-genome sequencing analysis revealed that an indel mutation in FCY2 also contributes to 5FC resistance. Furthermore, at least one out of seven adapted strains acquired enhanced 5FC tolerance without mutations in the 5FC conversion pathway. Thus, we demonstrate that FUR1 mutations are critical drivers of 5FC resistance in C. auris . IMPORTANCE: Candida auris is a high-priority human fungal pathogen, causing infection outbreaks of high mortality in healthcare settings. Antifungal combination therapy with 5-fluorocytosine (5FC) is one of the emerging approaches in treatment. However, acquired 5FC resistance traits have been a matter of concern. 5FC is taken up by fungal cells via a cytosine permease and further metabolized by a cytosine deaminase to 5-fluorouracil (5FU). 5FU is then converted by the Fur1 uracil phosphoribosyltransferase into a toxic antimetabolite that disrupts fungal RNA and DNA syntheses. Mutations in these proteins are commonly associated with 5FC resistance in fungal species. Here, we show that C. auris can rapidly develop resistance under 5FC selective stress owing to mutational inactivation of Fur1 function. Moreover, other mechanisms that bypass mutations in the 5FC conversion pathway may also contribute to 5FC resistance traits. Finally, we have developed a tailored bioinformatics workflow that facilitates the identification of polymorphisms associated with 5FC resistance in clinical isolates.